首页 > 资讯
ZUG, Switzerland -- (BUSINESS WIRE) --
Galderma Group AG (SWX:GALD):
NOT FOR DISTRIBUTION IN THE UNITED STATES OR IN ANY OTHER JURISDICTION IN WHICH SUCH DISTRIBUTION WOULD BE RESTRICTED BY APPLICABLE LAW OR REGULATION
Galderma successfully placed an inaugural bond with a total amount of CHF 500 million through a dual tranche offering:
- CHF 250 million bond, with a 4-year maturity and a 1.6% fixed-rate annual coupon
- CHF 250 million bond, with a 8-year maturity and a 1.9% fixed-rate annual coupon
The payment date of the bonds is September 27, 2024. The bonds will be listed on the SIX Swiss Exchange and are expected to be included in the domestic segment of the Swiss Bond Index (SBI). The bonds were placed under the lead management of UBS and Zürcher Kantonalbank.
To support the issuance of the bond, Galderma obtained two investment grade ratings from UBS and Zürcher Kantonalbank (BBB- “Improving” and BBB- “Stable” respectively).
The net proceeds of the transaction will be used for the partial refinancing of its existing Bank Term Loan issued at Initial Public Offering (IPO) and general purposes. This successful issuance is leverage-neutral and doesn’t affect Galderma’s guidance for full-year 2024 on net sales, Core EBITDA margin, leverage and interest cash expense for the second half of 2024, as last communicated on July 25, 2024.
About Galderma
Galderma (SIX: GALD) is the pure-play dermatology category leader, present in approximately 90 countries. We deliver an innovative, science-based portfolio of premium flagship brands and services that span the full spectrum of the fast-growing dermatology market through Injectable Aesthetics, Dermatological Skincare and Therapeutic Dermatology. Since our foundation in 1981, we have dedicated our focus and passion to the human body’s largest organ – the skin – meeting individual consumer and patient needs with superior outcomes in partnership with healthcare professionals. Because we understand that the skin we are in shapes our lives, we are advancing dermatology for every skin story. For more information: www.galderma.com
Disclaimer
This announcement does not constitute an offer to sell, a solicitation of an offer to buy any of the bonds described herein or any other securities issued by Galderma, or any kind of advice, nor shall there be any offer, solicitation or sale in any country or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any country or jurisdiction. This press release also does not constitute a prospectus as such term is understood pursuant to the Swiss Financial Services Act and not a prospectus under any other applicable laws. A decision to invest in the bonds mentioned herein should be solely made based on the prospectus published in connection with the offering. Except as required by law, Galderma does not have the intention or obligation to update any part of this publication.
- 搜索
-
- 04-11中医药专家于晓津携御君方专家团队出席2025年动脉粥样硬化健康论坛,以临床实证共话中医药科学价值
- 04-11易思脑与汇聚英才成功举行神经回馈训练国际认证助学中心挂牌仪式
- 04-11福城焕新颜 古韵谱华章——金融活水润泽郴州乡村振兴新图景
- 04-11加密货币交易量攀新高 香港券商转型交易量突破百亿居龙头
- 04-11保研录战略收购清华系创业团队“保研印象”,加速清北资源整合与技术创新
- 04-11杜丁副主任医师携御君方全国专家团队亮相2025年动脉粥样硬化健康论坛
- 04-11ProstaVive Reviews (BREAKING REPORT): Must-Read Warnings, Ingredients, Benefits & Real Results U
- 04-11ProstaVive: We Tested It for 90 Days—Our Full Month-by-Month Review and the Shocking Truth About Lon
- 04-11AquaSculpt Reviews (BREAKING): 27,000 CONSUMERS Tracked Over 90 Days—We Finally Have the Answer
- 04-11Bioventra Inc. Reports Surge in Sales of Flagship Wellness Products Mitolyn® and PrimeBiome® in Q1 2